Adagene, Incyte Partner on MSS CRC Therapy Combination
Event summary
- Adagene and Incyte are collaborating to evaluate the combination of Adagene’s muzastotug (ADG126) and Incyte’s INCA33890 in patients with microsatellite stable colorectal cancer (MSS CRC).
- A Phase 1 study is planned to begin in 2026, focusing on 3L MSS CRC patients with and without liver metastases, sponsored and conducted by Incyte.
- Adagene will supply muzastotug for the clinical trial.
- This collaboration represents the second instance of Adagene’s SAFEbody technology being paired with a PD-1 bispecific antibody.
The big picture
MSS CRC represents a significant unmet need in oncology, as existing immunotherapies have limited efficacy in this patient population. This collaboration highlights the ongoing effort to develop novel combination strategies to overcome resistance mechanisms. Adagene’s SAFEbody technology, if validated, could become a valuable platform for creating next-generation immunotherapies with improved safety profiles and broader applicability.
What we're watching
- Clinical Efficacy
- The initial Phase 1 data will be crucial in determining whether the combination demonstrates meaningful efficacy in MSS CRC, a notoriously difficult-to-treat cancer type.
- SAFEbody Adoption
- Further collaborations leveraging Adagene’s SAFEbody technology will indicate the broader appeal and value proposition of this masking approach in immuno-oncology.
- Regulatory Pathway
- The success of Incyte’s Phase 3 trial evaluating INCA33890 with standard chemotherapy will likely influence the development and regulatory pathway for the combination with muzastotug.
Related topics